Categories: US FDA Approval

Zydus Cadila gets USFDA nod for anti-hypertensive tablets

Ahmedabad, May 02, 2017:Healthcare player Zydus Cadila informed about receiving the final approval from the US drug regulator US Food and Drug Administration (USFDA) to market Olmesartan Medoxomil tablets in the US market.

The approval will allow the company to sell the drug in strengths of 5 mg, 20 mg and 40 mg. This is a day-one approval after the expiry of 181-day exclusivity, Zydus said here.

The drug is an anti-hypertensive and will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The estimated sales for Olmesartan is $982 million (IMS MAT February 2017), it added.

Businessline

The Pharma Times News Bureau

Recent Posts

8 Ways Insomnia Affects Skin Health & How To Avoid It

By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…

2 days ago

Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and Treatment

Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…

2 days ago

Healthcare Startups to Watch Out for in 2025

New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…

3 days ago

DKMS’s First Global Impact Report of 2023 Serves as New Ray of Hope for Blood Cancer Patients Worldwide

National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…

3 days ago

Sterling Biotech to start world’s first precision fermentation-based dairy protein factory in Gujarat

Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…

4 days ago

Pioneers in Senior Care, Antara, Partners with Leading Diagnostics Player Dr. Lal PathLabs to Strengthen its Geriatric Care Services

New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…

4 days ago